Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome

Summary

The goal of this clinical trial is to evaluate whether triple lipid-lowering therapy (atorvastatin, ezetimibe, and bempedoic acid) is more effective than dual therapy (atorvastatin and ezetimibe) in reducing LDL cholesterol levels in adults with acute coronary syndrome. It will also assess the safety of the treatment. The main questions it aims to answer are: * Does triple therapy result in greater reduction in LDL-C compared to dual therapy? * What adverse effects occur in participants receiving triple therapy? Researchers will compare triple therapy to dual therapy to determine its effectiveness in lowering LDL-C levels. Participants will: * Receive either dual or triple lipid-lowering therapy for 3 months * Attend regular follow-up visits for clinical assessment and laboratory testing * Undergo lipid profile evaluation at baseline and at the end of the study

Timeline

Start

2026-05-01

Primary completion

2026-10-01

Completion

2026-10-31

Publications

• Background Raposeiras-Roubin S, Abu Assi E, Jimenez Mendez C, Minguez de la Guia E, Perez Rivera JA, Marcos Mangas M, Ayesta A, Uribarri A, Jorge Perez P, Antunez Muinos PJ, Bonanad Lozano C, Carrasquer A, Viana-Tejedor A, Dominguez Erquicia P, Villar Ruiz A, Lopez Vazquez M, Aguilar Iglesias L, Alen Andremar A, Vidal Burdeus M, Martin Cabeza MM, Gonzalez Cambeiro MC, Bompart D, Gomez Polo JC, Garcia Garcia MT, Merino Merino A, Rozado J, Panera de la Mano JA, Salmeron Martinez F, Sanchez Corral E, Santos Sanchez I, Hernandez-Martos AV, Antelo Abejon A, Iniguez Romo A, Corbi-Pascual M, Ariza-Sole A. Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial. Circulation. 2026 Jan 20;153(3):140-149. doi: 10.1161/CIRCULATIONAHA.125.075388. Epub 2025 Nov 7.

Drugs

Indications